Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q
Summary
The Syntach system is powered by an implanted battery, avoiding a drive line through the skin and many of the negative side effects associated with current devices. Patrick also serves on the boards of Acorai and Scandinavian Real Heart.For the strategic role of Vice President of Regulatory and Quality Affairs, Syntach has hired senior leader Cansel Isikli, who brings 15 years of experience in medical device R&D and RA/Q. Prior to joining Syntach, Cansel served as VP R&D of the Occlutech Group where she managed the development and registration of over ten Class III medical devices. She also founded Prem R&D Consulting and CERES Healthcare Technologies.Tor Peters, Chairman of the Board commented: "It is our objective to revolutionize the way heart failure patients are treated while creating a company with the capability to offer this treatment on a global scale. We have assembled a fantastic team and paired with the great support from the EIC as well as the global cardiology and cardiac surgery communities, we are very optimistic about our future.